TCR2 Therapeutics News

News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP

Dow JonesJun 2, 2023 05:08

Adaptimmune Completes Merger With Fellow Immunology Company TCR2

Seeking AlphaJun 2, 2023 05:02

Adaptimmune Announces Completion of Strategic Combination With TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

newsfileJun 2, 2023 03:29

Shareholders of TCR2 Therapeutics (TCRR.US) increased their common stock holdings by 50,000 shares, worth about US$86,000

On May 31, it was reported that according to documents disclosed by the US Securities and Exchange Commission (SEC) on May 30, $TCR2 Therapeutics (TCRR.US) $shareholder TANG KEVIN C increased its common stock holdings at an average price of 1.72 US dollars per share on May 25, worth about 86,000 US dollars. The transaction involved other related parties: TANG CAPITAL MANAGEMENT LLC and TANG CAPITAL PARTNERS LP. Image source: SEC's official website What is a change in shareholding

Futu NewsMay 31, 2023 08:40

TCR2 Therapeutics Target Price Raised to $2.11 From $1.72 at Mizuho Securities

Dow JonesMay 12, 2023 18:56

Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying

BenzingaMay 11, 2023 21:25

TCR2 Therapeutics (TCRR) Receives a Hold From Mizuho Securities

TipRanksMay 11, 2023 20:45

TCR2 Therapeutics GAAP EPS of -$1.03 Misses by $0.34

Seeking AlphaMay 11, 2023 19:52

Press Release: TCR(2) Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Dow JonesMay 11, 2023 18:30

TCR2 Therapeutics 1Q Loss/Shr $1.03 >TCRR

Dow JonesMay 11, 2023 18:30

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights About 250+ Companies and 300+ Drugs

PRNewswireMay 8, 2023 23:01

FUBO, MULN and BAK Are Among Pre-market Gainers

Seeking AlphaMay 8, 2023 20:24

Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying

BenzingaMay 8, 2023 19:45

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR

PRNewswireApr 27, 2023 22:57

Fate Therapeutics (NASDAQ:FATE) and TCR2 Therapeutics (NASDAQ:TCRR) Head to Head Comparison

Financial News LiveApr 27, 2023 17:48

TCR2 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR2 Therapeutics Inc. - TCRR

BusinesswireApr 27, 2023 02:06

Head to Head Analysis: Fate Therapeutics (NASDAQ:FATE) & TCR2 Therapeutics (NASDAQ:TCRR)

Defense WorldApr 20, 2023 16:58

Adaptimmune, TCR Therapeutics Set May 30 for Shareholder Votes on Deal

Seeking AlphaApr 19, 2023 04:40

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky

Yahoo FinanceApr 15, 2023 21:30

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR

PR NewswireApr 12, 2023 01:40